

NCIC CLINICAL TRIALS GROUP

**GYNECOLOGY**

OVARIAN WORKING GROUP AGENDA

THE CHELSEA HOTEL, TORONTO, ON

ROOM: JAMES

SATURDAY MAY 2, 2014 8:00 A.M – 9:00 A.M

CHAIRS: DIANE PROVENCHER AND HELEN MACKAY

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

*To review new insights in the biology of ovarian cancer*

*To review the landscape of clinical trials in ovarian cancer*

*To review study contents/clinical trial proposals in ovarian cancer*

*To review existing partnerships and opportunities for new partnerships in ovarian cancer*

- 
1. Introduction - Canadian Ovarian trials landscape Mackay
  2. Open trials
    - **OV.21** Provencher/Mackay
    - **OV.23** Wilson/Oza
    - **OV.24** Lheureux/Oza
  3. Proposed Trials
    - **GOG 281**  
A Randomized Phase II/III Study To Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer  
*Open in the US and open in the UK*
    - **NRG-GY004 (GYN 9813)**  
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  
*Competes with NCIC CTG IND study*

- **NRG OV1405 (GYN 9814)**

A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent /persistent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

*Competes with NCIC CTG IND study*

4. IND Updates Tinker
5. PMH consortium update Oza
6. Any other business